The indications for Prevacid include: the short-term treatment of heartburn and other symptoms of gastroesophageal reflux disease (GERD); the short-term (up to eight weeks) healing, symptom relief and maintenance of healed erosive esophagitis, a condition in which the lining of the esophagus has been damaged; the short-term (up to eight weeks) treatment of active benign gastric (stomach) ulcers; the short-term (up to four weeks) treatment of duodenal ulcer (ulcers found on the first part of the small intestine); the maintenance of healed duodenal ulcer; the long-term treatment of pathological hypersecretory conditions (which involve the overproduction of stomach acid), including Zollinger-Ellison Syndrome. Controlled studies for maintenance indications did not extend beyond 12 months. Prevacid is also indicated for the healing and risk reduction of the recurrence of gastric (stomach) ulcers associated with NSAIDs (nonsteroidal anti-inflammatory drugs) in chronic NSAID users. Controlled studies for healing did not extend beyond eight weeks and controlled studies for risk reduction of recurrence did not extend beyond twelve weeks.

Symptomatic response to therapy does not preclude the presence of serious stomach problems. Prevacid is contraindicated in patients with known hypersensitivity to any component of the formulation. The most frequently reported adverse events include diarrhea (3.8%), abdominal pain (2.1%), and nausea (1.3%). For further information about Prevacid, please see the complete prescribing information below and visit www.prevacid.com.

Prevpac® (lansoprazole / amoxicillin / clarithromycin), a dosing package including Prevacid, is a convenient administration option for the multi-drug regimen used for eradication of H. pylori to reduce the risk of duodenal ulcer recurrence.

The most frequently reported side effects include diarrhea (7%), headache (6%), and taste perversion (5%). Symptomatic response to therapy does not preclude the presence of gastric malignancy. Eradication of H. pylori reduces the risk of duodenal ulcer recurrence. In patients who fail this therapy, susceptibility testing should be done if possible. If clarithromycin resistance is demonstrated, a non-clarithromycin containing regimen is recommended.

Prevpac is not recommended in patients with creatinine clearance <30mL/min. Prevpac is contraindicated in patients taking astemizole, cisapride, pimozide, terfenadine, ergotamine or dihydroergotamine. Colchicine toxicity has been reported with concomitant use of clarithromycin and colchicine, especially in geriatric patients; that has occurred in some patients with renal insufficiency. Patients should be monitored for clinical symptoms of colchicine toxicity. Clarithromycin may elevate digoxin serum concentrations. Serum digoxin levels should be carefully monitored while digoxin and clarithromycin are taken concomitantly. Clarithromycin should not be used in pregnant women except in circumstances where no alternative therapy is appropriate. The dose of clarithromycin should be reduced or the dosing interval lengthened in patients with severe renal impairment. Amoxicillin is contraindicated in patients who are allergic to penicillin. For further information about warnings, precautions or adverse reactions for amoxicillin and clarithromycin, please see the complete prescribing information for amoxicillin and for BIAXIN® Filmtab® (clarithromycin tablets, USP). To learn more about Prevpac, please see the complete prescribing information below.

Learn more about the following conditions:
Gastroesophageal Reflux Disease (GERD)
Ulcers

Prevacid Prescribing Information

Prevacid®
(lansoprazole)
Delayed-Release Capsules
For Delayed-Release Oral Suspension
SoluTab^TM Delayed-Release Orally Disintegrating Tablet

Prevpac®
(lansoprazole 30-mg capsules, amoxicillin 500-mg capsules, USP, and clarithromycin 500-mg tablets, USP)

Prevacid® I.V.
(lansoprazole)
for Injection

Prevacid® NapraPAC^TM
(lansoprazole delayed-release capsules and naproxen tablets kit)

With prescription Prevacid NapraPAC (lansoprazole delayed-release capsules and naproxen tablets kit) people with a history of gastric ulcer can continue treatment for osteoarthritis and rheumatoid arthritis, and reduce the risk of stomach ulcer coming back. Your results may vary. Controlled studies were conducted up to 12 weeks.

NSAIDS may increase the chance of a heart attack or stroke that can lead to death. PREVACID NapraPAC should not be used right before or after certain heart surgeries.

With any NSAID use, stomach or intestinal problems can occur without warning and can lead to death.

You should not take Naprosyn if you've had aspirin-sensitive asthma or allergic reactions to aspirin or other arthritis medicines. In rare cases, continued use of arthritis medicines may lead to serious stomach problems, such as bleeding, without warning signs. You should not take Naprosyn if you are taking other medications containing naproxen, such as Aleve® (naproxen sodium) or Anaprox® (naproxen sodium).

Tell your doctor if you have liver, kidney or fluid retention problems. Naprosyn should not be taken in late pregnancy. If you experience drowsiness or dizziness while taking Naprosyn, you should exercise caution when performing activities that require alertness.

The most frequently reported side effects of Naprosyn were constipation, heartburn, abdominal pain, nausea, headache, dizziness, drowsiness, itching, skin eruptions, bruising, ringing in the ear, excess fluid in tissues, and shortness of breath.

PREVACID NapraPAC should only be used exactly as prescribed. Please see the accompanying Complete Prescribing Information and Medication Guide for PREVACID NapraPAC hyperlinked above.